A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells by Bühler, P. et al.
Cancer Immunol Immunother (2008) 57:43–52 
DOI 10.1007/s00262-007-0348-6
123
ORIGINAL ARTICLE
A bispeciWc diabody directed against prostate-speciWc 
membrane antigen and CD3 induces T-cell mediated 
lysis of prostate cancer cells
P. Bühler · P. Wolf · D. Gierschner · I. Schaber · A. Katzenwadel · 
W. Schultze-Seemann · U. Wetterauer · M. Tacke · M. Swamy · 
W. W. A. Schamel · U. Elsässer-Beile 
Received: 15 December 2006 / Accepted: 23 May 2007 / Published online: 20 June 2007
© Springer-Verlag 2007
Abstract
Background Although cancer of the prostate is one of the
most commonly diagnosed cancers in men, no curative
treatment currently exists after its progression beyond
resectable boundaries. Therefore, new agents for targeted
treatment strategies are needed. Cross-linking of tumor
antigens with T-cell associated antigens by bispeciWc
monoclonal antibodies have been shown to increase anti-
gen-speciWc cytotoxicity in T-cells. Since the prostate-spe-
ciWc membrane antigen (PSMA) represents an excellent
tumor target, immunotherapy with bispeciWc diabodies
could be a promising novel treatment option for prostate
cancer.
Methods A heterodimeric diabody speciWc for human
PSMA and the T-cell antigen CD3 was constructed from
the DNA of anti-CD3 and anti-PSMA single chain Fv frag-
ments (scFv). It was expressed in E. coli using a vector
containing a bicistronic operon for co-secretion of the
hybrid scFv VHCD3-VLPSMA and VHPSMA-VLCD3. The
resulting PSMAxCD3 diabody was puriWed from the
periplasmic extract by immobilized metal aYnity chroma-
tography (IMAC). The binding properties were tested on
PSMA-expressing prostate cancer cells and PSMA-nega-
tive cell lines as well as on Jurkat cells by Xow cytometry.
For in vitro functional analysis, a cell viability test (WST)
was used. For in vivo evaluation the diabody was applied
together with human peripheral blood lymphocytes (PBL)
in a C4-2 xenograft-SCID mouse model.
Results By Blue Native gel electrophoresis, it could be
shown that the PSMAxCD3 diabody is mainly a tetramer.
SpeciWc binding both to CD3-expressing Jurkat cells and
PSMA-expressing C4-2 cells was shown by Xow cytometry.
In vitro, the diabody proved to be a potent agent for retarget-
ing PBL to lyze C4-2 prostate cancer cells. Treatment of
SCID mice inoculated with C4-2 tumor xenografts with the
diabody and PBL eYciently inhibited tumor growth.
Conclusions The PSMAxCD3 diabody bears the potential
for facilitating immunotherapy of prostate cancer and for
the elimination of minimal residual disease.
Keywords PSMAxCD3 bispeciWc diabody · 
Prostate cancer · T-cell targeting · Immunotherapy
Introduction
Currently, there is no eVective therapy for advanced pros-
tate cancer, which necessitates the development of new
and targeted therapies [13]. Among the diVerent identiWed
prostate antigens, the prostate-speciWc membrane antigen
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(PSMA) has been shown to represent an excellent target for
immunotherapy because it is (1) selectively expressed in
the prostate, (2) abundantly expressed as protein at all
stages and even upregulated in androgen-insensitive meta-
static disease, (3) presented at the cell surface without
being released into the circulation, and (4) associated with
enzymatic or signaling activity [10].
In the Weld of cancer immunotherapy research, the retar-
geting of T-cells to tumor cells by bispeciWc antibodies
(BsAbs) is an appealing therapeutic concept because cyto-
toxic T-cells range among the most potent eVector cells of
the immune system [31, 32]. The promise of BsAbs is an
antibody target-dependent, polyclonal T-cell response. This
does not depend on a speciWc T-cell receptor and MHC
class I/peptide complex, and can support serial killing by
cytotoxic T cells. Various strategies have been utilized for
the creation of BsAbs. In a Wrst generation, they have been
produced mainly by using quadroma technology [1]. The
most eVective approach for tumor rejection appeared to be
targeting via the CD3 component of the T-cell receptor
complex molecule. The feasibility and eVectiveness of this
immunotherapeutic concept have been studied extensively
in pre-clinical models and in some cases also in clinical tri-
als [2, 3]. However, the immunogenicity of these BsAbs
derived from rodent monoclonal antibodies was a major
drawback for their clinical use. Additionally, their produc-
tion and puriWcation in large quantities proved to be diY-
cult.
Recent advances in genetic engineering enabled the
preparation of recombinant BsAbs as dimeric antibody
fragments [12]. Diabodies are the smallest available BsAbs,
and the distance between the two antigen-binding sites is
suYcient to link two cells [21]. This compact size contrib-
utes to a low immunogenicity and a high tumor penetration
[34].
Kipriyanov et al. constructed a bispeciWc diabody with
dual speciWcity for both the human B-cell antigen CD19
and the -chain of the CD3/T-cell receptor complex, which
is able to retarget human lymphocytes to malignant B-cells
[16]. This construct was used in the present study as a
model for the generation of a diabody against PSMA and
the CD3 complex.
Material and methods
Cell lines
The human prostate carcinoma LNCaP subline C4-2 was
used as PSMA-positive target. As PSMA-negative control
the prostate cancer cell lines DU 145 and PC-3 were used.
The Jurkat cell line served as positive target for CD3 and
CD28.
Cells were purchased from the American Type Culture
Collection (ATCC, Rockville, MD, USA) and cultured in
RPMI 1640 medium supplemented with penicillin (100 U/
ml), streptomycin (100 mg/l) and 10% fetal calf serum
(Biochrom, Berlin, Germany) at 37°C in a humidiWed
atmosphere of 5% CO2.
Monoclonal antibodies and scFv 
The anti-PSMA scFv, called A5, directed against native
cell-adherent PSMA was obtained in our group from the
monoclonal antibody (mAb) 3/A12 as described previ-
ously. This scFv could be shown to be highly speciWc
for PSMA-expressing prostate cancer cells [8,  33]. The
anti-CD3 scFv was obtained from Dr. Kipriyanov, DKFZ,
Heidelberg, Germany [14]. Anti-CD28 mAb (15E8) was
obtained from Dr. Miedema, Netherlands Red Cross Blood
Transfusion Service.
Expression vectors for diabody construction
The E. coli K12 strain XL1-blue (Stratagene, La Jolla, CA,
USA) was used as the cloning and expression host. The
plasmid pHOG-3-19, containing the recombinant DNA for
VHCD3 and VLCD19, and the plasmid pHOG-19-3, con-
taining the recombinant DNA for VHCD19 and VLCD3,
were obtained from Dr. Kipriyanov, DKFZ, Heidelberg,
Germany [16].
scFv and diabody expression and puriWcation
E. coli XL1-blue cells (La Jolla, CA, USA) transformed
with the plasmid for diabody or scFv were grown overnight
in 2xYT-AG-medium, then diluted 1:20 and grown as
600 ml cultures at 37°C. When cultures reached OD 0.8,
bacteria were pelleted by centrifugation at 1,500g for
10 min and resuspended in the same volume of fresh 2xYT-
medium containing 50 g/ml ampicillin, 0.4 M sucrose and
1 mM IPTG. Then the bacteria were incubated at room
temperature for 18–20 h. Cells were harvested by centrifu-
gation at 5,000g for 10 min and 4°C. To isolate soluble
periplasmic proteins, the pelleted bacteria were resus-
pended in 30 ml of ice-cold 50 mM Tris–HCl, 20%
sucrose, 1 mM EDTA (pH 8.0). After incubation for 1 h on
ice, the spheroblasts were centrifuged at 20,000g for 30 min
at 4°C yielding soluble periplasmic extract in the super-
natant, which was dialyzed against 50 mM Tris–HCl, 1 M
NaCl, (pH 7.0).
PuriWcation was achieved by immobilized metal aYnity
chromatography (IMAC). This was performed using a 1 ml
column of chelating Sepharose (Amersham Biosciences,
Freiburg, Germany) charged with Ni2+ and equilibrated
with a buVer containing 50 mM Tris–HCl and 1 M NaClCancer Immunol Immunother (2008) 57:43–52 45
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(pH 7.0). The periplasmatic extract was loaded on the col-
umn, washed with 20 column volumes of equilibration
buVer containing 30 mM imidazole and then eluted with
the same buVer containing 250 mM imidazole. The eluted
material was dialyzed against PBS. Determination of the
protein content was performed with the Micro BCA Protein
Reagent Kit (Pierce Biotechnology, Rockford, IL, USA)
according to the manufacturer’s instructions.
Western blot analysis
SDS-PAGE was performed by standard procedures accord-
ing to the manufacturer’s instructions (Invitrogen,
Karlsruhe, Germany). For Western blotting, the diabody
and scFvs were subjected to SDS-PAGE and transferred to
nitrocellulose membranes. The blots were blocked over-
night in PBS containing 5% non-fat milk and incubated
with a peroxidase-coupled anti-human-c-myc antibody
(Roche Diagnostics, Mannheim, Germany) for 1 h, and
then developed by using 3,3-diaminobenzidine as sub-
strate. For Blue Native (BN)-PAGE [22, 23] analysis, the
diabody and scFvs were diluted to 0.2 g in 10 l BN buVer
(500 mM 6-aminohexanoic acid, 20 mM NaCl, 10% glyc-
erol, 2 mM EDTA, 20 mM bis–Tris, pH 7 and protease
inhibitors) and resolved on 4–18% BN-PAGE as described
[29]. The proteins were transferred semi-dry to a PVDF
membrane, and Western blotting was performed as above,
and developed with the ECL chemiluminescence system.
The high molecular weight calibration kit for native elec-
trophoresis (GE Healthcare) was also loaded and stained
with Coomassie brilliant blue for molecular weight stan-
dards.
Flow cytometry
The target cells were freshly harvested from tissue culture
Xasks and a single cell suspension was prepared in PBS with
3% FCS and 0.1% NaN3. Approximately, 105 cells were
incubated with 50 l of scFv or diabody for 1 h on ice. After
three rounds of washing with PBS, 25 l anti-human-c-myc
mAb (Roche Diagnostics, Mannheim, Germany) was added
at 10 g/ml and incubated for 40 min on ice. After three
washings with PBS, the cells were incubated with 25 l of
goat anti-mouse Ig-RPE (Becton Dickinson, Mountain
View, CA, USA) for 40 min on ice. For inhibition experi-
ments with mouse anti-PSMA mAb, a rat anti-c-myc mAb
(Serotec LTD, Oxford, UK) and goat anti-rat IgG (H + L)-
RPE (Catlag Lab Burlingame, CA, USA) were taken. The
cells were then washed repeatedly and resuspended in
200 l PBS containing 1 g/ml propidium iodide, 3% FCS
and 0.1% NaN3. The relative Xuorescence of stained cells
was measured using a FACScan® Xow cytometer and the
CellQuest® software (Becton Dickinson). Mean Xuores-
cence intensity values (MFI) were considered after subtrac-
tion of the background staining with secondary antibody and
RPE-labeled goat anti-mouse Ig alone.
Preparation of eVector cells
Human peripheral blood mononuclear cells (PBMC) were
isolated from fresh buVy coats of random donors by Ficoll
(Pharmacia, Freiburg, Germany) density gradient centrifuga-
tion. The cells of the interphase were washed twice, counted
and tested for viability with trypan blue dye. The PBMC
were incubated overnight in 10 ml RPMI 1640 medium sup-
plemented with penicillin (100 U/l), streptomycin (100 mg/l)
fetal calf serum (10%) and low-dose IL-2 (10 U/ml) at 37°C,
5% CO2 leading to the adherence of monocytes. The non-
adherent PBL were used as eVector cells.
Measurement of in vitro cytotoxicity 
The metabolism of the red tetrazolium salt WST to a water-
soluble formazan dye was determined according to the
manufacturer’s instructions (Roche Diagnostics, Mann-
heim, Germany). Target cells were seeded at 1.5 £ 104
cells/well of a 96-well plate and grown for 24 h until a con-
Xuent cell layer was formed. Dilutions of the diabody in
aliquots of 50 l/well were added to the plates together with
the eVector cells at a target:eVector ratio of 1:10 and incu-
bated for 48 h at 37°C and 5% CO2. After this time, the
cultures were pulsed with 15 l/well WST reagent and
incubated for 90 min at 37°C and 5% CO2. Then the spec-
trophotometrical absorbance of the samples was measured
at 450 nm (reference 690 nm). As control for the PBL
background in each WST experiment, PBL were incubated
at the same lymphocyte concentration without tumor cells
for 48 h and developed with WST. The value of these wells
was then subtracted from the values of the test wells.
SCID mouse Xenograft model
Six-week-old SCID mice were purchased from Charles
River Laboratories (Sulzfeld, Germany). The animals were
kept under sterile and standardized environmental condi-
tions (20 § 1°C room temperature, 50 § 10% relative
humidity, 12 h light–dark rhythm) and received autoclaved
food, water and bedding. All experiments were performed
according to the German animal protection law with per-
mission from the responsible local authorities. For tumor
inoculation, 2 £ 106 C4-2 cells in 100 l PBS were mixed
with 100 l Matrigel (Collaborative Biomedical Products,
Chicago, USA) at 4°C and administered s.c. at the right
Xank of each animal. Growing tumors were measured daily
using a caliper in two perpendicular dimensions. Between
day 6 and 12 after tumor inoculation, the animals were46 Cancer Immunol Immunother (2008) 57:43–52
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treated i.v. either with peripheral blood lymphocytes (PBL)
plus diabody, or with PBL alone, or with the vehicle. When
the tumors of the control group reached a diameter of
12 mm, the animals were killed by CO2 gas overdose. From
the tumor diameters, the mean radius (r) and hence the
tumor volumes were calculated using the formula V =4 /
3r3. Statistical analysis of the mean tumor volume of the
corresponding treatment groups versus the vehicle control
group was calculated performing a Student’s t test.
Results
Construction of the diabody plasmid
In the plasmid pHOG-3-19, the sequence for VLCD19 was
exchanged against VLPSMA by a PCR and the restriction
sites Hind III and Not I, thus generating the plasmid pHO-
GCD-3-PSMA (Fig. 1a). In the plasmid pHOG-19-3, the
sequence of VHCD19 was exchanged against VHPSMA by
using the restriction sites NcoI and Hind III for the genera-
tion of pHOG-PSMACD-3 (Fig. 1b). The expression plas-
mid of the PSMAxCD3 diabody for co-secretion of the two
hybrid scFvs was constructed by ligation of the Bgl II/XbaI
restriction fragment from pHOGCD-3-PSMA comprising
the vector backbone and the Bgl II/Xba I fragment from
pHOG-PSMACD-3 (Fig. 1c). Both hybrid scFv operons are
followed by sequences coding for a human c-myc tag for
immunodetection and a hexahistidine tag for puriWcation.
Diabody expression and puriWcation
Upon induction with IPTG, the PSMAxCD3 diabody was
expressed by co-secretion of the two hybrid scFvs
VHPSMA-VLCD3 and VHCD3-VLPSMA from E.coli XL1-
blue cells as periplasmatic native protein and was also
released into the culture medium. The periplasmatic extract
was puriWed by IMAC. Yields were estimated by the pro-
tein content according to BCA-testing and the 32 KD band
on SDS-gels compared to a BSA standard. Between 100
and 300 g diabody per liter of culture were obtained from
the periplasmatic extract. Purity of the diabody was deter-
mined by SDS-PAGE and Coomassie brilliant blue staining
(Fig. 2a). The diabody was kept under sterile conditions
and stored at ¡80°C.
Analysis of the PSMAxCD3 diabody
To analyze the quaternary structure of the diabody, it was
resolved by gel-electrophoresis in either reducing denatur-
ing conditions (SDS-PAGE) or native conditions (BN-
PAGE), followed by Western blotting. Under denaturing,
reducing conditions the PSMAxCD3 diabody was detected
as protein double band at 32 kD (Fig. 2b, lane 1), corre-
sponding to the two hybrid scFvs, VHPSMA-VLCD3 and
VHCD3–VLPSMA. Separation of the diabody into a double
band was only seen by Western blotting and not in the Coo-
massie-stained SDS gel, as smaller amounts were loaded
for Western blotting, which allows higher resolution. When
separated under native conditions by BN-PAGE [28, 29],
the diabody is mainly present as a band whose molecular
weight (»150 kD) corresponds to a tetramer (Fig. 2c, lane
1). Additional bands of higher MW are visible, possibly
representing complexes of a larger order. The anti-PSMA
scFv alone is also a tetramer (lane 2), whereas the anti-CD3
scFv is a dimer at »70 kD (Fig. 2c, lane 3). Together these
Wndings indicate that the variable regions of the anti-PSMA
scFv are responsible for tetramerization.
Fig. 1 Construction scheme for the PSMAxCD3 diabody plasmid (c)
from the hetero scFv VHCD3–VLPSMA (a) and VHPSMA-VLCD3 (b).
The positions of the sequences of the variable regions of the light and
heavy chains of the anti-PSMA-scFv and the anti-CD3-scFv, the ribo-
some binding sites (rbs), pelB leader sequences (pelB), c-myc epitopes
(c-myc), hexa-histidine tags (His6) and stop codons (stop) are indicatedCancer Immunol Immunother (2008) 57:43–52 47
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Antigen-binding speciWcity of the PSMAxCD3 diabody 
and the parental scFvs
Flow cytometric experiments demonstrated a speciWc bind-
ing of the PSMAxCD3 diabody to PSMA-positive C4-2
cells (Fig. 3b) and to CD3-expressing Jurkat cells (Fig. 3f).
The mean Xuorescence intensities (MFI) at saturating con-
ditions were about 30 on C4-2 cells and about 15 on Jurkat
cells and therefore comparable to those obtained using
the parental monospeciWc anti-PSMA scFv (Fig. 3a) and
anti-CD3 scFv (Fig. 3e). In contrast to the PSMAxCD3
diabody, the separately induced hybrid scFv VHPSMA-
VLCD3 and scFv VHCD3–VLPSMA did not show any
binding to either C4-2 cells (Fig. 3c, d) or Jurkat cells
(Fig. 3g, h). This indicates that both variable regions (VH
and VL) are necessary to reconstitute the binding site of an
antibody. The saturation curves of the PSMAxCD3 diabody
and the parental anti-PSMA scFv at concentrations between
0.5 and 500 nM on C4-2 cells is shown in Fig. 4a. From
this graph, a half-maximal saturation was calculated to be
100 nM for the diabody and 80 nM for the scFv. The corre-
sponding curves of the diabody and the anti-CD3 scFv on
Jurkat cells are shown in Fig. 4b. Half-maximal saturation
was calculated to be 30 nM for the diabody and the scFv.
Binding of the PSMAxCD3 diabody to C4-2 cells was
inhibited by parental monoclonal antibody 3/A12 (Fig. 5a)
and binding to Jurkat cells was inhibited by mAb OKT3
(Fig. 5b).
No binding of the diabody was found on PSMA- and
CD3-negative DU145 and PC-3 cells. This is in accordance
with the parental anti-PSMA scFv, which was shown to be
highly speciWc for PSMA-expressing cells and did not bind
to the PSMA-negative target cell lines DU 145, PC-3,
HeLa, MCF7, HCT15, MB453, K562 and SW20 [33]. The
speciWcity of the parental anti-CD3 scFv has also been
shown previously [14].
The in vitro stability of the diabody was tested by bind-
ing experiments before and after incubation at 37°C for
24 h. Under these conditions, the binding capacity was
reduced by 25%. Storage of the diabody at 4°C or frozen at
¡20°C for several weeks brought about no alteration in the
binding capacity.
Induction of speciWc cytotoxicity by the PSMAxCD3 
diabody in vitro
The ability of the bispeciWc diabody to induce tumor cell
lysis by redirecting T-cell mediated cytotoxicity was inves-
Fig. 2 a SDS-PAGE of the PSMAxCD3 diabody (lane D). The gel
was stained with Coomassie brilliant blue. Lane M contains a molecu-
lar weight marker. b Gel electrophoresis under denaturing, reducing
conditions of PSMAxCD3 diabody (lane 1), anti-PSMA scFv (lane 2)
and anti-CD3 scFv (lane 3). Proteins were subjected to reducing SDS-
PAGE and transferred to a Western blot membrane. The blot was
developed with peroxidase-coupled anti-c-myc-mAb, and 3,3-diamino-
benzidine. Lane M contains a prestained molecular weight marker. c
Gel electrophoresis under native conditions of PSMAxCD3 diabody
(lane 1), anti-PSMA scFv (lane 2) and anti-CD3 scFv (lane 3). Proteins
were separated by BN-PAGE and Western blotted with the peroxidase-
coupled anti-c-myc-mAb and the ECL detection system. The molecu-
lar weights of the native protein standards are indicated on the left in
kilo Daltons48 Cancer Immunol Immunother (2008) 57:43–52
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tigated with PBL from healthy donors, which were mono-
cyte depleted. PSMA-expressing C4-2 prostate cancer cells
served as target cells and PSMA-negative DU-145 cells as
controls.
In these experiments with an eVector–target ratio of
10:1, the PSMAxCD3 diabody appeared to be potent in
retargeting PBL to lyze the PSMA-positive C4-2 cells,
whereas PSMA-negative DU145 cells were not lyzed at the
same conditions (Fig. 6a). PBL from diVerent donors varied
as seen by the error bars. The PBL alone (at ET ratio 10:1)
and the diabody alone at 15 nM were not toxic to both cell
lines. Cytotoxicity could be blocked by addition of an
excess of parental mAb 3/A12 (Fig. 6b). The addition of
anti-PSMA scFv or anti-CD3 scFv together with PBL
showed only minimal cytotoxic activity compared to the
PSMAxCD3 diabody (Fig. 7). Addition of anti-CD28 mAb
for co-stimulation at concentrations between 100 g and
5 mg/ml brought about no enhancement of the diabody
eVects on C4-2 cells (data not shown).
EVect of the PSMAxCD3 diabody on xenotransplanted 
C4-2 tumors in SCID mice
The in vivo eVects of the PSMAxCD3 diabody were tested
in SCID mice xenotransplanted with the human LNCaP
subline C4-2. Mice were engrafted with 2 £ 106 C4-2 cells
s.c., which was shown to generate palpable tumors in more
than 95% of the animals.
In a Wrst series of four animals, toxicity of the
PSMAxCD3 diabody was tested at doses of 5, 10, 15 and
20 g per injection. Doses up to 15 g were well tolerated.
For therapy, a series of 21 animals were used. On day 6
after tumor inoculation, the animals were randomized into
three groups of seven animals. Group a was treated with
5 £ 106 PBL as eVector cells on day 6 and additionally with
10 g PSMAxCD3 diabody on days 6, 7, 10, 11, and 12.
Group b was treated with 5 £ 106 human PBL on day 6.
The animals of group c were treated with saline vehicle. All
animals were killed on day 20 after tumor inoculation,
Fig. 3 Binding of anti-PSMA 
scFv (a), PSMAxCD3 diabody 
(b), hybrid scFv VHPSMA-
VLCD3 (c) and hybrid scFv 
VHCD3–VLPSMA (d) to 
PSMA-positive C4-2 cells. 
Binding of anti-CD3 scFv (e), 
PSMAxCD3 diabody (f), hybrid 
scFv VHPSMA-VLCD3 (g) and 
hybrid scFv VHCD3–VLPSMA 
(h) to CD3-positive Jurkat cells. 
Cells were stained with diabody 
or scFv at 300 nM, mouse-anti-
c-myc mAb and goat anti-mouse 
Ig-RPE. Histograms represent 
logarithms of PE-Xuorescence 
on Xow cytometer. Negative 
control (gray histograms) with 
mouse-anti-c-myc mAb, and 
goat anti-mouse Ig-RPECancer Immunol Immunother (2008) 57:43–52 49
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when the tumors of the control animals had reached 12 mm
diameter and/or begun to ulcerate.
In the saline-treated control group, the animals devel-
oped fast growing tumors between day 10 and 15 after
tumor inoculation. In contrast, animals receiving human
PBL showed reduced tumor growth. Animals receiving
human PBL and additionally PSMAxCD3 diabody showed
a delayed starting point of tumor growth and, Wnally,
clearly reduced tumor growth (Fig. 8). The diVerences in
the mean tumor volume of the animals of group a (diabody
+ PBL) and group c (vehicle) proved to be signiWcant
(P = 0.001), as well as the diVerences in the mean tumor
volume of the animals of group a and group b (PBL alone)
were signiWcant (P =0 . 0 4 ) .
Discussion
The limited options in the treatment of prostate cancer have
encouraged the search for new immunotherapeutic strate-
gies. The retargeting of cellular eVector systems by bispec-
iWc antibodies is a promising approach. Such recombinant
diabodies have been generated against a number of tumor-
associated antigens, but not yet against prostate cancer. By
virtue of its abundant and restricted surface expression on
prostate epithelial cells, PSMA represents an attractive anti-
gen for a targeted therapy. However, in contrast to other
tumor-associated antigens [19], there are only very few
approaches that use PSMA. The reason for this may be that
only few mAbs and scFvs binding to cell-adherent PSMA
have yet been published [5, 11, 17, 20, 30].
For the construction of the PSMAxCD3 diabody
described in the present paper, we used the recombinant
Fig. 4 Saturation curves of the 
PSMAxCD3 diabody and the 
parental anti-PSMA scFv to 
PSMA-positive C4-2 cells (a) 
and of PSMAxCD3 diabody 
and parental anti-CD3 scFv to 
CD3-positive Jurkat cells (b) at 
concentrations between 0.5 
and 500 nM
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Fig. 5 Inhibition of the binding of PSMAxCD3 diabody to C4-2 cells
by parental mAb 3/A12 (a) and to Jurkat cells by parental mAb OKT3
(b). Cells were preincubated with the mAb at diVerent concentrations
(5–200 nM) and then stained with PSMAxCD3 diabody at 200 nM, rat
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DNA of an anti-CD3 scFv, which had been modiWed to
improve its stability and folding in bacteria [14]. The sec-
ond scFv was highly speciWc for cell-adherent PSMA [33].
The molecular design of the diabody and its bicistronic
secretion was in accordance with the CD19 £ CD3 diabody
published by Kipriyanov et al. [16]. This construct has been
shown to be a dimer in native conditions with two antigen-
binding sites at opposite ends of the molecule, separated by
65 A. This size has been suggested as being optimal
because it provides rapid tissue penetration, high target
retention and rapid blood clearance [12]. Interestingly, our
PSMAxCD3 diabody proved to be a tetramer as analyzed
by BN-PAGE. This indicates the presence of two binding
sites each for CD3 and PSMA. Kipriyanov et al. have
shown that a tetravalent CD3 £ CD19 tandem diabody was
superior to the corresponding heterodimeric diabody [15].
Fig. 6 a EVects of treatment of PSMA-positive C4-2 cells (black) and
PSMA-negative DU 145 cells (gray) with PSMAxCD3 diabody and
PBL eVector cells (eVector:target ratio 10:1). Cell viability was mea-
sured in WST assays after 48 h incubation as described. The results are
expressed as the percentage of viable cells compared to the control
(= cells incubated with PBS). Additionally, the data of treatment with
diabody alone at 15 nM without PBL (Dia) and the data of treatment
with PBL alone without diabody (PBL) are given. The results were
corrected for the background of the eVector cells. Data represent mean
values of determinations with three diVerent blood donors each in trip-
licate. Standard deviations (SD) are indicated by the error bars. b
Blocking of the cytotoxic activity of the PSMAxCD3 diabody by an
excess of parental anti-PSMA mAb. C4-2 cells were incubated with
PBL and diabody at 12 nM together with parental mAb 3/A12 at diVer-
ent concentrations. Cell viability was measured in WST assays after
48 h incubation. Determination was with three diVerent donors. SD are
indicated by the error bars
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Currently it is not known whether our diabody forms a
dimer of dimers or whether it is a bispeciWc tetrabody [12].
Flow cytometry measurements have shown that it binds to
CD3-positive Jurkat cells and to PSMA-positive C4-2 cells
with an aYnity similar to that of the parental scFvs. In vitro
testing showed the diabody’s ability to induce an eYcient
lysis of PSMA-expressing target cells by human PBL. Fur-
thermore, the diabody has proven to be clearly more eVec-
tive than either of the parental scFv alone. However, in this
in vitro test the antitumor activity of the diabody was not
enhanced in the presence of anti-CD28 mAb, which
induces a well-known co-stimulatory signal [4]. This may
be partly explained by the use of preactivated PBL and is in
accordance with other in vitro and in vivo studies [9, 16,
18, 25].
The ultimate goal of any antitumor immunotherapy is
the in vivo eradication of tumor cells. In a Wrst animal
experiment we tested the potency of the PSMAxCD3 dia-
body to mediate T-cell dependent tumor lysis in a fairly
stringent in vivo model of immunodeWcient mice bearing a
subcutaneously growing human prostate cancer xenograft.
The therapy scheme was chosen according to literature sug-
gestions [24] and aimed to treat small tumor masses. There-
fore, we started the application of preactivated PBL and
diabody as early as 6 days after tumor inoculation. With
this treatment regime we could show that the PSMAxCD3
diabody is eVective against prostate cancer cells in vivo in
the absence of any T-cell co-stimulatory compounds. The
eYcacy under these conditions supports that human T-cells
did reach the tumor site after injection into the tail vein and
could act suYciently long with a suYcient number of func-
tional T-cells. The limited number and accessibility of
human T-cells in our model may underestimate the poten-
tial of the PSMAxCD3 diabody in humans where cytotoxic
T-cells are present in larger numbers and found widespread
in the organism. This availability of T-cells would make a
repeated application of the diabody much more eYcient,
raising the opportunity to treat larger tumor masses. The
current mouse model rather allows the investigation of a
minimal residual disease situation. This is in agreement
with other authors who showed good antitumor eVects
in human B-lymphoma xenografts after application of
CD19 £ CD3 diabody within a few days after tumor inocu-
lation [6, 7]. A direct comparison of early and late diabody
application was shown by Schlereth et al. [24] in a human
colon carcinoma xenograft model after application of an
EP-CAMxCD3 diabody. These authors also found a much
better tumor remission rate in the groups with early applica-
tion due to a limited half-life of human lymphocytes in the
SCID mouse, a smaller workload for the cytotoxic T-cells
and an increased penetration in smaller tumors.
In comparison to other models, a shortcoming of our C4-
2 xenograft model is the short experimental time. Since the
C4-2 tumors are very fast growing and mostly ulcerating,
the animals had to be euthanized 20–25 days after tumor
inoculation. A slower growing cell line that allows longer
observation times may be used in further studies. For fur-
ther preclinical development, pharmacological properties
as well as immunological side eVects have to be tested in
an immunocompetent individual. However, since the
CD19 £ CD3 diabody could be safely applied to chimpan-
zees [26], and also used in a Wrst clinical trial [12], no
severe side eVects like a cytokine storm in the Phase I trial
of the anti-CD28 monoclonal antibody [27] may be
expected with the PSMAxCD3 diabody.
In conclusion, the present study describes a Wrst
approach to establish a new immunotherapy with retarget-
ing of eVector T cells for prostate cancer. We have demon-
strated that the PSMAxCD3 diabody induces highly
eYcient T-cell mediated killing of prostate cancer cells.
Therefore, this diabody deserves further development in
preclinical and clinical settings as a promising therapeutic
agent.
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